With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.
[(Cp*)Ir(mu-Cl)Cl]2 (39.8 mg, 0.05 mmol) was dissolved in methanol(20 mL) followed by addition of the 4-methyl-4?-carboxy-2,2?-bipyridine ligand (21.4 mg, 0.10 mmol). The mixture was stirred at313 K overnight. The final yellow solution was filtered, concentratedand NH4PF6 (163 mg, 1.0 mmol) was added to the solution. This solutionwas kept at 277 K overnight. The yellow precipitate was collectedby filtration and dried under vacuum. Yield 66 mg, 91%; 1H NMR(400 MHz, d4-MeOD, 298 K): delta 9.11 (d, 1H, J = 5.8 Hz), 9.00 (s, 1H),8.81 (d, 1H, J=5.8 Hz), 8.61 (s, 1H), 8.26 (d, 1H, J=5.8 Hz), 7.71 (d,1H, J = 6.1 Hz), 2.70 (s, 3H), 1.72 (s, 15H); 13C NMR (125 MHz, d4-MeOD, 298 K): 165.79, 158.15, 155.99, 155.08, 154.10, 152.47,143.72, 131.21, 129.19, 126.65, 124.58, 91.28, 21.39, 8.67; high resolutionESI-MS m/z calcd for [(M-PF6-H)+Na]+ 599.1040, found599.1038.
103946-54-9, As the paragraph descriping shows that 103946-54-9 is playing an increasingly important role.
Reference£º
Article; Zhang, Wen-Ying; Banerjee, Samya; Imberti, Cinzia; Clarkson, Guy J.; Wang, Qian; Zhong, Qian; Young, Lawrence S.; Romero-Canelon, Isolda; Zeng, Musheng; Habtemariam, Abraha; Sadler, Peter J.; Inorganica Chimica Acta; vol. 503; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI